{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:39Z","timestamp":1791231459651,"version":"4.1.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The role of signal transducers and activators of transcription 5 (STAT5) in chronic myelogenous leukemia (CML) is controversial. To clarify the role of STAT5 signaling in P210BCR\/ABL leukemogenesis, P210 was introduced into primary murine STAT5A-deficient (STAT5A\u2013\/\u2013) bone marrow (BM) cells, which, unlike STAT5A\/5B double knockout BM cells, have no major intrinsic hematopoietic defects. Interestingly, only 21% of mice reconstituted with P210-transduced STAT5A\u2013\/\u2013 BM cells developed classic CML, compared with 80% to 100% of P210\/STAT5A+\/+ and P210\/STAT5A+\/\u2013-reconstituted animals. The remainder of P210\/STAT5A\u2013\/\u2013 animals died from an acute B-cell lymphoblastic leukemia (ALL)\u2013like disease (32%) or a CML\/ALL mix (47%), reflecting impairment in the induction and maintenance of CML, which normally predominates in this mouse model. Of mice that ultimately developed CML, P210\/STAT5A\u2013\/\u2013 animals had prolonged survival and increased myeloid immaturity. Importantly, reconstitution of wild-type mice with BM cells coexpressing P210 and dominant-negative STAT5 also profoundly reduced the incidence of CML, without impairing the induction of ALL. Altogether, these findings indicate that STAT5 and STAT5A play an important role in the pathogenesis of the CML-like disease in mice. A greater understanding of the STAT5 target genes involved in CML induction may lead to new therapeutic targets that influence CML progenitor cell biology.<\/jats:p>","DOI":"10.1182\/blood-2005-10-4110","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T02:43:37Z","timestamp":1141785817000},"page":"4917-4925","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":98,"title":["STAT5 signaling is required for the efficient induction and maintenance of CML in mice"],"prefix":"10.1182","volume":"107","author":[{"given":"Dan","family":"Ye","sequence":"first","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine; and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wolff","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine; and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine; and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumin","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine; and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert L.","family":"Ilaria","sequence":"additional","affiliation":[{"name":"From the Division of Hematology\/Oncology, Department of Medicine; and the Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111805374198700_REF1","doi-asserted-by":"crossref","unstructured":"Wertheim JA, Miller JP, Xu L, He Y, Pear WS. The biology of chronic myelogenous leukemia:mouse models and cell adhesion. Oncogene. 2002;21: 8612-8628.","DOI":"10.1038\/sj.onc.1206089"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Ren R. Dissecting the molecular mechanism of chronic myelogenous leukemia using murine models. Leuk Lymphoma. 2002;43: 1549-1561.","DOI":"10.1080\/1042819021000002875"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138: 819-830.","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res. 2004;28: 21-28.","DOI":"10.1016\/j.leukres.2003.10.005"},{"key":"2019111805374198700_REF5","doi-asserted-by":"crossref","unstructured":"Skorski T. BCR\/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene. 2002;21: 8591-8604.","DOI":"10.1038\/sj.onc.1206087"},{"key":"2019111805374198700_REF6","doi-asserted-by":"crossref","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344: 1031-1037.","DOI":"10.1056\/NEJM200104053441401"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99: 1928-1937.","DOI":"10.1182\/blood.V99.6.1928"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99: 3530-3539.","DOI":"10.1182\/blood.V99.10.3530"},{"key":"2019111805374198700_REF9","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346: 645-652.","DOI":"10.1056\/NEJMoa011573"},{"key":"2019111805374198700_REF10","doi-asserted-by":"crossref","unstructured":"Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003;22: 7389-7395.","DOI":"10.1038\/sj.onc.1206942"},{"key":"2019111805374198700_REF11","doi-asserted-by":"crossref","unstructured":"Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293: 876-880.","DOI":"10.1126\/science.1062538"},{"key":"2019111805374198700_REF12","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16: 2190-2196.","DOI":"10.1038\/sj.leu.2402741"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004;11: 35-43.","DOI":"10.1097\/00062752-200401000-00006"},{"key":"2019111805374198700_REF14","doi-asserted-by":"crossref","unstructured":"Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol. 2003;40: 80-82.","DOI":"10.1053\/shem.2003.50046"},{"key":"2019111805374198700_REF15","doi-asserted-by":"crossref","unstructured":"Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med. 1996;183: 811-820.","DOI":"10.1084\/jem.183.3.811"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Ilaria RL Jr, Van Etten RA. P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271: 31704-31710.","DOI":"10.1074\/jbc.271.49.31704"},{"key":"2019111805374198700_","unstructured":"Frank DA, Varticovski L. Bcr\/abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats. Leukemia. 1996;10: 1724-1730."},{"key":"2019111805374198700_","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13: 247-254."},{"key":"2019111805374198700_REF19","doi-asserted-by":"crossref","unstructured":"Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159: 4720-4728.","DOI":"10.4049\/jimmunol.159.10.4720"},{"key":"2019111805374198700_REF20","doi-asserted-by":"crossref","unstructured":"Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med. 1999;189: 1229-1242.","DOI":"10.1084\/jem.189.8.1229"},{"key":"2019111805374198700_REF21","doi-asserted-by":"crossref","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Jove R, Koenderman L. STAT5 activation by Bcr-Abl contributes to transformation of K562 leukemia cells. Blood. 1999;94: 1108-1112.","DOI":"10.1182\/blood.V94.3.1108.415k07_1108_1112"},{"key":"2019111805374198700_REF22","doi-asserted-by":"crossref","unstructured":"Horita M, Andreu EJ, Benito A, et al. Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med. 2000;191: 977-984.","DOI":"10.1084\/jem.191.6.977"},{"key":"2019111805374198700_REF23","doi-asserted-by":"crossref","unstructured":"Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD. STAT5 activation contributes to growth and viability in Bcr\/Abl-transformed cells. Blood. 2000;95: 2118-2125.","DOI":"10.1182\/blood.V95.6.2118"},{"key":"2019111805374198700_REF24","doi-asserted-by":"crossref","unstructured":"Jacobberger JW, Sramkoski RM, Frisa PS, et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr\/Abl kinase activity. Cytometry. 2003;54A: 75-88.","DOI":"10.1002\/cyto.a.10063"},{"key":"2019111805374198700_REF25","doi-asserted-by":"crossref","unstructured":"Huang M, Dorsey JF, Epling-Burnette PK, et al. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene. 2002;21: 8804-8816.","DOI":"10.1038\/sj.onc.1206028"},{"key":"2019111805374198700_REF26","doi-asserted-by":"crossref","unstructured":"Gesbert F, Griffin JD. Bcr\/Abl activates transcription of the Bcl-X gene through STAT5. Blood. 2000;96: 2269-2276.","DOI":"10.1182\/blood.V96.6.2269"},{"key":"2019111805374198700_REF27","doi-asserted-by":"crossref","unstructured":"Sexl V, Piekorz R, Moriggl R, et al. Stat5a\/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr\/abl-induced transformation are independent of stat5. Blood. 2000;96: 2277-2283.","DOI":"10.1182\/blood.V96.6.2277"},{"key":"2019111805374198700_REF28","doi-asserted-by":"crossref","unstructured":"Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93: 841-850.","DOI":"10.1016\/S0092-8674(00)81444-0"},{"key":"2019111805374198700_REF29","doi-asserted-by":"crossref","unstructured":"Bunting KD, Bradley HL, Hawley TS, Moriggl R, Sorrentino BP, Ihle JN. Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. Blood. 2002;99: 479-487.","DOI":"10.1182\/blood.V99.2.479"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Bradley HL, Hawley TS, Bunting KD. Cell intrinsic defects in cytokine responsiveness of STAT5-deficient hematopoietic stem cells. Blood. 2002;100: 3983-3989.","DOI":"10.1182\/blood-2002-05-1602"},{"key":"2019111805374198700_REF31","doi-asserted-by":"crossref","unstructured":"Bradley HL, Couldrey C, Bunting KD. Hematopoietic-repopulating defects from STAT5-deficient bone marrow are not fully accounted for by loss of thrombopoietin responsiveness. Blood. 2004;103: 2965-2972.","DOI":"10.1182\/blood-2003-08-2963"},{"key":"2019111805374198700_REF32","doi-asserted-by":"crossref","unstructured":"Cui Y, Riedlinger G, Miyoshi K, et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol. 2004;24: 8037-8047.","DOI":"10.1128\/MCB.24.18.8037-8047.2004"},{"key":"2019111805374198700_REF33","doi-asserted-by":"crossref","unstructured":"Moriggl R, Sexl V, Kenner L, et al. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 2005;7: 87-89.","DOI":"10.1016\/j.ccr.2004.12.010"},{"key":"2019111805374198700_REF34","unstructured":"Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1: 136-138."},{"key":"2019111805374198700_REF35","doi-asserted-by":"crossref","unstructured":"Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow. Blood. 1998;92: 3780-3792.","DOI":"10.1182\/blood.V92.10.3780"},{"key":"2019111805374198700_REF36","doi-asserted-by":"crossref","unstructured":"Ilaria RL, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood. 1999;93: 4154-4166.","DOI":"10.1182\/blood.V93.12.4154"},{"key":"2019111805374198700_REF37","doi-asserted-by":"crossref","unstructured":"Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990;247: 824-830.","DOI":"10.1126\/science.2406902"},{"key":"2019111805374198700_REF38","doi-asserted-by":"crossref","unstructured":"Finer MH, Dull TJ, Qin L, Farson D, Roberts MR. kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood. 1994;83: 43-50.","DOI":"10.1182\/blood.V83.1.43.43"},{"key":"2019111805374198700_REF39","doi-asserted-by":"crossref","unstructured":"Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993;90: 8392-8396.","DOI":"10.1073\/pnas.90.18.8392"},{"key":"2019111805374198700_REF40","doi-asserted-by":"crossref","unstructured":"Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev. 1997;11: 179-186.","DOI":"10.1101\/gad.11.2.179"},{"key":"2019111805374198700_REF41","doi-asserted-by":"crossref","unstructured":"Ilaria RL Jr. Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18: 525-543.","DOI":"10.1016\/j.hoc.2004.03.003"},{"key":"2019111805374198700_REF42","doi-asserted-by":"crossref","unstructured":"Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189: 1399-1412.","DOI":"10.1084\/jem.189.9.1399"},{"key":"2019111805374198700_REF43","doi-asserted-by":"crossref","unstructured":"Eliazer S, Spencer J, Ye D, Olson E, Ilaria RL Jr. Alteration of mesodermal cell differentiation by EWS\/FLI-1, the oncogene implicated in Ewing's Sarcoma. Mol Cell Biol. 2003;23: 482-492.","DOI":"10.1128\/MCB.23.2.482-492.2003"},{"key":"2019111805374198700_REF44","doi-asserted-by":"crossref","unstructured":"Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98: 2808-2816.","DOI":"10.1182\/blood.V98.9.2808"},{"key":"2019111805374198700_REF45","doi-asserted-by":"crossref","unstructured":"Zhang X, Wong R, Hao SX, Pear WS, Ren R. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype. Blood. 2001;97: 277-287.","DOI":"10.1182\/blood.V97.1.277"},{"key":"2019111805374198700_REF46","doi-asserted-by":"crossref","unstructured":"Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOXA9. Proc Natl Acad Sci U S A. 2002;99: 7622-7627.","DOI":"10.1073\/pnas.102583199"},{"key":"2019111805374198700_REF47","doi-asserted-by":"crossref","unstructured":"Risser R, Stockert E, Old LJ. Abelson antigen: a viral tumor antigen that is also a differentiation antigen of BALB\/c mice. Proc Natl Acad Sci USA. 1978;75: 3918-3922.","DOI":"10.1073\/pnas.75.8.3918"},{"key":"2019111805374198700_REF48","doi-asserted-by":"crossref","unstructured":"Kirken RA, Malabarba MG, Xu J, et al. Prolactin stimulates serine\/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem. 1997;272: 14098-14103.","DOI":"10.1074\/jbc.272.22.14098"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Feldman GM, Rosenthal LA, Liu X, et al. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. 1997;90: 1768-1776.","DOI":"10.1182\/blood.V90.5.1768"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Zhang S, Fukuda S, Lee Y, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med. 2000;192: 719-728.","DOI":"10.1084\/jem.192.5.719"},{"key":"2019111805374198700_REF51","doi-asserted-by":"crossref","unstructured":"Kabotyanski EB, Rosen JM. Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem. 2003;278: 17218-17227.","DOI":"10.1074\/jbc.M301578200"},{"key":"2019111805374198700_REF52","doi-asserted-by":"crossref","unstructured":"Elefanty AG, Hariharan IK, Cory S. bcr-abl, the hallmark of chronic myeloid leukemia in man, induces multiple hematopoietic neoplasms in mice. EMBO J. 1990;9: 1069-1078.","DOI":"10.1002\/j.1460-2075.1990.tb08212.x"},{"key":"2019111805374198700_REF53","doi-asserted-by":"crossref","unstructured":"Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia. Blood. 2003;101: 5010-5013.","DOI":"10.1182\/blood-2002-10-3059"},{"key":"2019111805374198700_REF54","doi-asserted-by":"crossref","unstructured":"de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L. STAT5-dependent CyclinD1 and Bcl-xL expression in Bcr-Abl-transformed cells. Mol Cell Biol Res Commun. 2000;3: 299-305.","DOI":"10.1006\/mcbr.2000.0231"},{"key":"2019111805374198700_REF55","doi-asserted-by":"crossref","unstructured":"Kieslinger M, Woldman I, Moriggl R, et al. Anti-apoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 2000;14: 232-244.","DOI":"10.1101\/gad.14.2.232"},{"key":"2019111805374198700_REF56","doi-asserted-by":"crossref","unstructured":"Campbell LJ, Patsouris C, Rayeroux KC, Somana K, Januszewicz EH, Szer J. BCR\/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. Cancer Genet Cytogenet. 2002;139: 30-33.","DOI":"10.1016\/S0165-4608(02)00615-5"},{"key":"2019111805374198700_","doi-asserted-by":"crossref","unstructured":"Morel F, Bris MJ, Herry A, et al. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Eur J Haematol. 2003;70: 235-239.","DOI":"10.1034\/j.1600-0609.2003.00046.x"},{"key":"2019111805374198700_REF58","doi-asserted-by":"crossref","unstructured":"Gadzicki D, von Neuhoff N, Steinemann D, et al. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet Cytogenet. 2005;159: 164-167.","DOI":"10.1016\/j.cancergencyto.2004.09.021"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4917\/1280133\/zh801206004917.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4917\/1280133\/zh801206004917.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T17:59:36Z","timestamp":1683395976000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/12\/4917\/129319\/STAT5-signaling-is-required-for-the-efficient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,15]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-10-4110","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,15]]}}}